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Abstract Amylin is an important control of nutrient
fluxes because it reduces energy intake, modulates nutrient
utilization by inhibiting postprandial glucagon secretion,
and increases energy disposal by preventing compensatory
decreases of energy expenditure in weight-reduced indi-
viduals. The best investigated function of amylin which is
cosecreted with insulin is to reduce eating by promoting
meal-ending satiation. This effect is thought to be mediated
by a stimulation of specific amylin receptors in the area
postrema. Secondary brain sites to mediate amylin action
include the nucleus of the solitary tract and the lateral
parabrachial nucleus, which convey the neural signal to the
lateral hypothalamic area and other hypothalamic nuclei.
Amylin may also signal adiposity because plasma levels of
amylin are increased in adiposity and because higher
amylin concentrations in the brain result in reduced body
weight gain and adiposity, while amylin receptor antago-
nists increase body adiposity. The central mechanisms
involved in amylin’s effect on energy expenditure are
much less known. A series of recent experiments in ani-
mals and humans indicate that amylin is a promising option
for anti-obesity therapy especially in combination with
other hormones. The most extensive dataset is available for
the combination therapy of amylin and leptin. Ongoing
research focuses on the mechanisms of these interactions.
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Introduction
This review focuses on three aspects of amylin’s roles in
the control of eating and energy homeostasis. In the first
part, the current knowledge on how the hindbrain mediates
amylin action is summarized. An interesting phenomenon
is that there is a large overlap in various areas between
different satiating signals despite some differences at the
behavioral level; in most instances, it is unknown how the
brain differentiates between similar signals. Second, the
potential role of amylin as adiposity signal in addition to its
satiating action is discussed. Finally, based on the exciting
data gained from animal experiments, the therapeutic
potential of amylin in obesity, in particular using combi-
nation therapies, is discussed.
Pancreatic beta-cells are the major source of circulating
amylin. Meal-associated fluctuations of circulating amylin
levels are thought to directly reflect changes in beta-cell
secretion; the contribution of other amylin-secreting cells
to circulating amylin levels is considered minor. Further, it
is also believed that fluctuations in beta-cell secretion like
the postprandial increase are the physiological basis for
amylin’s effect on eating and energy homeostasis [1].
Mediation of amylin action by specific amylin receptors
Amylin actions are mediated by a membrane bound
receptor which is also present in the area postrema (AP),
the presumed primary site for most amylin actions (for
review, see [2]). The amylin receptor is a heterodimer of
the type-a or type-b calcitonin receptor (CTR) and receptor
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activity modifying proteins (RAMP). The CTR represents
the core receptor protein which obtains specific amylin
binding properties by co-expression of one of the known
RAMPs in the same cell [3–5]. Amylin receptors typically
derive from the co-expression of CTR with RAMP1 or 3
[6, 7]; RAMPs confer specificity of the CTR to amylin by
altering CTR pharmacology from calcitonin-preferring to
amylin-preferring receptors. RAMPs regulate the transport
of the core receptors to the cell surface and their glyco-
sylation state and therefore influence ligand specificity
[4, 8].
Amylin binds strongly to the AP; the CTR, RAMP1, and
RAMP3 are all densely expressed in the AP; further,
amylin-induced neuronal activation, as assessed by c-Fos
mRNA colocalizes with CTR(a) and RAMP3 mRNA in the
rat AP [9–12]. However, despite the evidence that all
structural components of functional amylin receptors are
present in the AP, and that the AP is necessary for amylin
action (see below), it still remains to be shown that the
CTR, RAMP1, or RAMP3 all co-localize in amylin-sen-
sitive AP neurons. Further, it has not yet been tested
whether the site-specific ablation of one of the critical
components of the functional amylin receptor in AP neu-
rons is sufficient to abolish amylin action.
Amylin acts as a satiation signal (see also Fig. 1
for working model of amylin action)
The best investigated function of amylin is the role as a
signal of satiation [13]. In the complex system that controls
eating, amylin is believed to be a physiological control of
meal size [14, 15], because it meets the critical criteria for a
physiological endocrine satiation signal. First, in humans,
rats and other species food intake leads to a marked and
rapid increase in plasma amylin concentration within
minutes after meal onset; this increase correlates with the
amount eaten [16, 17]. In rats, eating a 5 g test meal after
an overnight fast leads to an immediate rise in endogenous
plasma amylin levels from about 3–5 to 15–20 pmol/l
within 5–10 min. Second, functional amylin receptors, i.e.
the heterodimers of CTR plus RAMPs appear to be
expressed in the AP and the AP is necessary for amylin’s
effect on eating. Third, low, near physiological doses of
exogenous amylin that increase plasma amylin levels only
about two times compared to postprandial levels inhibit
eating [18]; considering the many interactions of amylin
with other controls of eating and the enhanced eating
inhibitory effect by their combined administration [19–21],
we presume that this important criterion is therefore suf-
ficiently met. Fourth, amylin-deficient mice have been used
to study the specific removal of amylin [22]. These mice
show some expected phenotypes, such as (at least
temporary) overeating and increased adiposity [23, 24].
However, whether these changes persist throughout life
and whether they can be rescued by amylin replacement
still needs to be studied; at least under acute conditions,
amylin reduces eating in amylin knockout mice in a way
similar to wildtype controls. Fifth, amylin antagonists like
AC187 increase eating and meal size when administered
peripherally [25] or centrally [26]; AC187 administered
into the AP blocks the anorectic effect of peripheral amylin
and stimulates eating and intake by an increase in meal size
[27]. Finally, amylin and amylin analogues reduce meal
size without producing signs of conditioned taste aversion
or visceral illness [28–31]. Overall, the data indicate that
amylin acts as a physiological satiating hormone in rats.
Amylin does produce comparable behavioral effects in
humans but the crucial tests for its physiological relevance
in humans have not yet been done.
Amylin action in the brainstem
The AP is one of several brain regions that show strong
amylin binding in amylin receptor autoradiography studies
[12]. The anorectic effect of amylin seems to be mediated
by a direct humoral action on neurons in the AP; this direct
activation by circulating amylin is possible because the AP
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Fig. 1 Satiation diagram. The working model assumes that norad-
renergic (NA) neurons in the area postrema (AP) mediate amylin’s
satiating effect. Intracellular signaling systems involved in amylin
action include cGMP and pERK but their necessity for amylin-
induced NA neurotransmission needs to be investigated. AP projec-
tions reach the lateral parabrachial nucleus (LPB) directly or
indirectly via the nucleus of the solitary tract (NTS). The NTS is
the most likely site for the interaction between cholecystokinin (CCK)
and amylin. Projections from the LPB reach several hypothalamic
nuclei such as the lateral hypothalamic area (LHA), the ventromedial
hypothalamus (VMH) where histamine receptors of the H1 subtype
(H1R) may be involved and where amylin interacts with leptin (see
also Fig. 2), and perhaps the hypothalamic arcuate nucleus (ARC).
3V third cerebral ventricle
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lacks a functional blood–brain barrier [32, 33]. Some of the
data that indicate that activation of the AP is necessary for
amylin’s satiating effect are summarized here.
First evidence that the satiating effect of peripheral
amylin is mediated by direct action on AP neurons was
provided by studies showing that neither subdiaphragmatic
vagotomy nor specific hepatic branch vagotomy or capsa-
icin-induced lesions of peripheral neural afferents that
project to the brain reduced amylin’s effect. Amylin’s
effect was, however, abolished in rats with specific AP
lesions [31, 32, 34–38]. Further, local amylin administra-
tion into the AP reduced meal size and AC187 had the
opposite effect; AC187 also abolished the eating inhibitory
effect of peripheral amylin [27]. Consistent data were
produced in electrophysiological and immunohistochemi-
cal studies which also suggested a direct influence of
amylin on the AP [39–43]. Interestingly, the AP also seems
to be necessary for amylin’s action to inhibit gastric
emptying, because ablation of the AP but not of vagal
afferents blocks this effect [31, 44–47] (see also ‘‘Amylin’s
effect on gastric emptying is also mediated by AP
neurons’’).
Brainstem intracellular mechanisms mediating amylin
signaling
Numerous studies have investigated the specific intracel-
lular signaling mechanisms that are activated by amylin
and potentially mediate its action. Some of these studies
relied on the use of neuronal activation markers such as
c-Fos; more recent studies provided evidence for the
necessity of certain other intracellular mechanisms for
amylin action.
A commonly used marker for amylin-activated brain
areas is based on the expression pattern of the immediate
early gene product c-Fos detected by immunohistochem-
istry [9, 31, 42, 48, 49]. These experiments helped to define
specific amylin-activated areas in the brain; in addition to
the AP, the neuroaxis mediating amylin action also com-
prises the nucleus of the solitary tract (NTS) and the lateral
parabrachial nucleus (LPB). However, the functional cor-
relate of these findings remains unknown; in other words,
whether amylin-induced c-Fos expression in the AP or
other brain areas is necessary for amylin action is
unknown. Specific tests in this respect have not yet been
performed, but see also ‘‘AP neurons are also sensitive to
nutrients’’.
Immunohistological c-Fos studies have also shown that
exogenous and endogenous amylin activate the same brain
structures. Meal access after a 24-h food deprivation period
caused neuronal activation in the AP and NTS comparable
to that of exogenous amylin, and this response in the AP
was blocked by AC187. The latter indicates that
endogenous amylin contributes to the activation of the AP
in refed animals [42].
Despite its widespread use, the mapping of activated
brain areas using c-Fos protein expression has several
inherent disadvantages. As already mentioned, the func-
tional role of c-Fos formation after amylin stimulation or
other stimuli is not clear. First, the eating-inhibitory effect
of acute amylin occurs within a few minutes after admin-
istration, but c-Fos-protein expression is typically not
detectable before 30 min after the stimulus; the latter
could, of course, also be due to the limited sensitivity of
available antibodies for small amounts of c-Fos (which,
however, may be biologically active) [50]. Second, c-Fos
immunoreactivity reflects only one specific point in time,
and third, it only depicts areas activated but not inhibited
by a given stimulus.
Considering these disadvantages, cGMP formation may
be more useful to depict amylin action in the AP. Immu-
nohistological and electrophysiological studies suggested
that amylin exerts excitatory effects in AP neurons that are
mediated by an increased formation of the intracellular
second messenger cyclic guanosine monophosphate
(cGMP) [40]. Further, local AP injection of a membrane-
permeable analogue of cGMP decreased eating similar to
amylin by a meal size effect [27]. Because most neurons
showing increased formation of cGMP after amylin express
the CTR (unpublished), formation of cGMP may be func-
tionally involved in amylin’s eating-inhibitory effect.
However, it still needs to be tested whether cGMP for-
mation in the AP is necessary for amylin to reduce eating,
i.e. whether the inhibition of its formation prevents amy-
lin’s effect.
A series of recent experiments identified the extracel-
lular signal-regulated kinase 1 and 2 (ERK 1/2) cascade as
a useful intracellular marker for amylin action; in fact,
rapid phosphorylation of ERK may be functionally
involved in amylin’s effect on eating. ERK 1/2 is one of the
four members of the mitogen-activated protein kinase
family; it is a highly conserved signaling cascade and is
involved in various cellular processes. Activation of this
pathway leads to a rapid ERK1/2 phosphorylation which
results in the activation of gene transcription but also in
acute neuronal responses; the latter responses are typically
linked to the activation or inhibition of ion channels and
hence to neuronal excitability [51–54]. This feature makes
the ERK cascade an interesting candidate signaling system
for the study of many rapid behaviors, including meal
termination by satiating peptides like amylin.
Because amylin had been demonstrated to stimulate
ERK signaling in osteoclasts which carry specific amylin
receptors [7, 55], we recently tested whether amylin acti-
vates this signaling pathway in the AP and whether this
may be functionally relevant for amylin action. In fact,
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amylin time- and dose-dependently induced ERK phos-
phorylation in the AP with a peak effect between 10 and
15 min after peripheral amylin, which is at a time when
amylin’s satiating effect is fully developed [28, 39]. Fur-
ther, amylin-induced ERK phosphorylation in AP neurons
partly overlapped with positive staining for the CTR,
indicating that the ERK cascade seems to be activated in
amylin-sensitive AP neurons; pERK staining also over-
lapped with the expression of dopamine-beta-hydroxlase
(DBH), a key enzyme in noradrenaline synthesis (see
below and [56]). Finally, prior administration of U0126, an
inhibitor of ERK phosphorylation into the 4th brain ven-
tricle, reduced the acute eating inhibitor effect of amylin at
least under certain experimental conditions [43, 56].
Overall, these studies indicate a potential functional role of
ERK cascade activation in amylin’s anorectic effect.
It had previously been demonstrated that the ERK
pathway is activated in the NTS by the administration of
peripheral CCK; similar to amylin, the anorectic action of
CCK seems to critically depend on this pathway because
pharmacological blockade of ERK phosphorylation by
U0126 attenuated CCK’s immediate anorectic response
[57, 58]. Interestingly, the NTS is a site of convergence for
a variety of anorectic signals including amylin, which may
modulate CCK’s anorectic effect via the AP/NTS region
[19, 59].
One result of the amylin-induced activation of AP neu-
rons seems to be an increased expression of DBH, the key
enzyme in noradrenaline synthesis, and the subsequent
release of noradrenaline possibly in the NTS or LPB [56].
Recent studies indicate that noradrenergic neurons within
the AP mediate amylin’s anorexigenic effects. First, a large
proportion of amylin-activated AP neurons are noradren-
ergic because the number of DBH and c-Fos double-labeled
neurons was higher in amylin- than in saline-injected rats
[56]. Second, a specific lesion of about 50% of all norad-
renergic neurons in the AP with the chemotoxin saporin was
sufficient to abolish the anorexigenic effect of peripheral
amylin. Third, the saporin-induced lesion of these NA-
neurons also reduced amylin’s ability to induce c-Fos
expression in AP neurons; the number of amylin-activated
neurons correlated with the number of remaining NA-neu-
rons in the AP, indicating that rats with larger NA-lesions,
and hence fewer remaining DBH-positive neurons, also
displayed lower numbers of amylin-activated AP neurons.
AP neurons are also sensitive to nutrients
Amylin-sensitive AP neurons also seem to act as direct
sensors for a variety of nutrients. Electrophysiological
studies have, e.g., shown that amylin and glucose co-acti-
vate AP neurons [41]. A direct functional correlate of the
amylin and glucose co-sensitivity of AP neurons has been
described in respect to amylin’s effect to reduce the rate of
gastric emptying (see also ‘‘Amylin’s effect on gastric
emptying is also mediated by AP neurons’’); this effect was
absent under hypoglycemic conditions [60]. Similarly,
recent studies indicated that amylin reduced eating in rats
under euglycemic and hyperglycemic, but not under
hypoglycemic, conditions (unpublished). Teleologically, it
seems plausible that amylin’s action to inhibit nutrient
availability should be restricted to situations when energy
stores are plentiful, and that amylin should not limit the
supply of nutrients at a time when they are urgently needed.
Recent findings indicate that dietary protein may also
influence the action of amylin on AP neurons. Considering
the general assumption that increased c-Fos expression
exemplifies neuronal activation [50], and that amylin
reduces eating via the AP [32], it was surprising that a low
dose of peripheral amylin that decreased eating induced
strong c-Fos expression in the AP of 24-h fasted rats, but
not in rats fed ad libitum [61]. Interestingly, amylin also
induced a strong c-Fos response in rats fed a nutrient-
deficient non-caloric mash (NCM). Subsequent trials with
nutrient specific supplementation of the NCM diet sug-
gested that protein or perhaps single amino acids, but not
fat or carbohydrates, attenuate the amylin-induced c-Fos
response in the AP. Finally, parenteral injection of an
amino acid mixture also attenuated the amylin-induced
c-Fos expression in the AP in fasted rats, and amylin’s
anorectic action was stronger in rats fed a 1% protein diet
(1% weight/weight) compared to rats fed an isocaloric diet
with higher protein content (8–18%) [61, 62]. The mech-
anisms underlying these phenomena and the functional
implications are not clear, and it needs to be tested whether
specific amino acids may directly reduce the effect of
amylin to activate AP neurons. Interestingly, these studies
do show that the effect of amylin to reduce eating and to
induce c-Fos expression may be dissociated under certain
conditions.
Amylin’s effect on gastric emptying is also mediated
by AP neurons
The stomach and gastric emptying play an important role in
the overall control of eating [63]. Gastric wall distension
produces an anorectic signal that is conveyed to the central
nervous system, and in particular to the NTS via gastric
vagal and splanchnic afferents [64–66]. Most but not all
[28] studies suggested that anorectic doses of amylin also
reduce gastric emptying in rats and humans [46, 67, 68];
the effect seems to be physiologically relevant because
AC187 accelerated gastric emptying in rats [69].
These observations are interesting regarding the phe-
nomenon of accelerated gastric emptying in human type 1
diabetics and insulin-requiring type 2 diabetics; this defect
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contributes to postprandial hyperglycaemia and may
therefore be responsible for part of the negative long-term
consequences of diabetes mellitus (e.g. [70]). The amylin
analogue pramlintide has similar effects in human patients
like amylin in rats, and amylin, but not insulin, normalizes
gastric emptying in animal models of type 1 diabetes [46,
67, 71–74]. Similar to amylin’s anorectic action, the effect
on gastric emptying seems to depend on a direct action in
the AP [44] but not on vagal afferents [47, 75, 76]. Inter-
estingly, amylin’s inhibitory effect on gastric emptying is
overridden under hypoglycaemic conditions (see also ‘‘AP
neurons are also sensitive to nutrients’’; [60]); this is pos-
sibly explained by the co-sensitivity of AP neurons to
amylin and glucose [41].
Because the lowest effective amylin doses to reduce
meal size or to slow gastric emptying are comparable [77],
it was postulated that amylin’s effect on gastric emptying
contributes to amylin’s anorectic effect under normal
feeding conditions; however, the former effect does not
seem to be necessary for the latter to occur. First, both
effects are pharmacologically distinguishable [1, 78], and
second, amylin also reduces eating under sham-feeding
conditions and, hence, when gastric and postgastric feed-
back signals are eliminated [79]. Because higher doses
were necessary to reduce sham-feeding than real-feeding
[79], amylin may synergistically interact with other nega-
tive feedback signals to reduce food intake; these may
include gastric feedback [77], CCK [19, 21, 59, 79], and
possibly other signals [20].
Amylin’s anorectic effect is not secondary
to a reduction in drinking
Because food intake is usually coupled to water intake
[80], reduced drinking could theoretically lead to a sec-
ondary reduction in eating. There is, however, so far no
experimental evidence that amylin reduces eating second-
ary to an effect on water intake; while amylin induces a
parallel reduction of eating and drinking when both food
and water are present, an independent primary amylin-
induced reduction of drinking in the absence of food has
not been documented [29, 35, 81]. Further, amylin did not
reduce water intake in a sham feeding paradigm [79]. This
suggests that the inhibitory effect of amylin on water intake
in the presence of food, i.e. when an anorectic effect is
present, is secondary to a reduction in feeding.
Neural pathways beyond the AP processing amylin
signaling
The combination of receptor binding studies ([12]; see also
[9]), behavioral experiments with local injections [27], and
behavioral experiments with rats that carry lesions of the
entire AP [31, 32] or of specific neurons within the AP [56]
all clearly indicate that the AP is the primary target for
amylin and necessary for its action. The activation of AP
neurons seems to be synaptically transmitted to the fore-
brain via the NTS and the LPB. Rats with lesions of the AP
or the LPB do not eat less in response to amylin [32, 82].
Further, the amylin-induced c-Fos expression was absent in
areas rostral to the site of lesion; hence, no c-Fos was
observed in the NTS, LPB, and central nucleus of the
amygdala (CeA) in AP-lesioned, or in the CeA in LPB-
lesioned, rats. Neuronal tracing studies with anterograde
and retrograde tracers confirmed the direct links between
these amylin-activated areas. These studies also identified
the LPB as the primary relay between the hindbrain and the
hypothalamus, including the lateral hypothalamic area
(LHA), where amylin reduces fasting-induced c-Fos
expression [42, 48], and the ventromedial hypothalamus
(VMH) where histamine H1 receptors may be implicated in
amylin’s effect on eating [83].
Other gastrointestinal hormones that inhibit eating like
cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1),
and peptide YY 3-36 (PYY) all produce relatively similar
activation patterns in the brain [21, 49, 84–87], but it
remains unclear how the brain distinguishes between these
different inputs. At present, the most commonly used
technique to study brain activation, i.e. c-Fos immunocy-
tochemistry, is very useful to define a general activation
pattern. However, and as briefly discussed above, the use
of c-Fos is limited because only one specific time point
can be assessed from a single animal, because only neu-
ronal activation but not neuronal inhibition is detected,
and because c-Fos is expressed only after the behavioral
satiating response has occurred. If the various satiation
signals acted at slightly different time points across
a meal, it seems rather unlikely that the poor temporal
resolution of c-Fos immunostaining would allow the
capturing of these differences. Hence, the functional
implications of c-Fos expression in respect to the process
of satiation remain unknown. Alternative strategies like in
vivo imaging, perhaps using functional magnetic reso-
nance, may help to characterize more specifically and in a
time-dependent manner the brain pathways specifically for
each signal.
Role of histamine in amylin signaling
Hypothalamic histamine is involved in the control of food
intake and body weight [88–92]. Increased concentrations
of central histamine reduce feeding via histamine
H1 receptors [90, 93], whereas a blockade of central his-
tamine H1 receptors increases food intake. Additional
studies showed that the H1 receptors in the VMH and
Amylin controls energy homeostasis 1951
123
paraventricular (PVN) hypothalamic nuclei, which are the
areas richest in hypothalamic histamine and H1 receptors
[89, 94], play the major role in this regard [89].
Various studies underlined the importance of histamine
and in particular of H1 receptors in amylin’s effect on
eating. Part of these experiments was performed using H1
receptor-deficient mice (H1rKO mice). As expected, the H3
receptor antagonist thioperamide, which reduces food
intake in rats [88] by enhancing the synthesis and release of
endogenous histamine [95], produced no anorectic effect in
H1Rko mice but only in wild-type (wt) controls [96].
Further, we also observed an increased body weight gain in
H1Rko mice compared to wt controls; this was associated
with an increased fat pad mass [97] and a slight increase in
basal food intake in the H1Rko mice. Hence, the phenotype
of the H1rko mice is consistent with the overall importance
of the histaminergic system and H1 receptors in the control
of food intake and body weight.
Functional H1 receptors seem to be essential for amylin
or its agonist salmon calcitonin (sCT) to reduce eating.
sCT is structurally and functionally related to amylin [98]
and reduces feeding by interaction with amylin receptors
[99]. The stronger and prolonged effect of sCT compared
to amylin [99] can be explained by sCT’s irreversible
binding to amylin receptors [100] and their persistent
activation [101]. The latter seems to occur without sig-
nificant receptor desensitization. In contrast to wt control
animals, the anorectic actions of amylin and of sCT were
absent in H1Rko mice unless extremely high doses were
used [96, 97]. It is important to note that the lack of H1
receptors did not produce an unspecific insensitivity to
anorectic stimuli because the H1rko mice exhibited a
normal response to anorectic doses of CCK [96]; conse-
quently, histamine H1 receptors are not necessary for the
transmission of CCK’s anorectic action. These data con-
firm previous studies that CCK’s anorectic effect does not
depend on the histaminergic but rather the serotoninergic
system [102], and they also underline the specificity of
the observed effects in respect to amylin or amylin
agonists.
The findings in the H1rko mice complemented previous
studies. First, we had demonstrated that pretreatment of
rats with the H3 receptor agonists imetit or R-a-methyl-
histamine, which block the release of endogenous
histamine via presynaptic histamine H3 receptors, reduced
amylin’s inhibitory effect on feeding in rats [102]. Further,
amylin did not reduce eating in rats that were pretreated
with the H1 receptor antagonist chlorpheniramine admin-
istered directly into the VMH [83]. Overall, we therefore
concluded that the amylin-induced activation of AP neu-
rons directly or indirectly leads to an increase in
hypothalamic histamine release to bring about amylin’s
effect by acting on hypothalamic histamine H1 receptors,
most likely within the VMH (see also Figs. 1, 2).
The H1rko mice also provided interesting findings in
respect to leptin. Morimoto et al. and Yoshimatsu et al.
[103, 104] had already shown that the central histamin-
ergic system is involved in leptin’s anorectic effect
because a specific inhibitor of histidine decarboxylase (a-
fluoromethylhistidine; FMH), which is a key enzyme in
histamine synthesis, abolished the anorectic effect of
leptin in mice; further, leptin’s inhibitory effect on feeding
was absent in H1Rko mice [104, 105]. The latter was also
confirmed by us [96]; only very high leptin doses pro-
duced some reduction in eating [97], indicating that other
neurotransmitters also seem to be involved in leptin action
[106].
Together, these findings raise the question whether the
central nervous signaling pathways for amylin which acts
through activation of AP neurons, and leptin which acts
primarily via the hypothalamus, converge via the hista-
minergic system in the VMH. This conclusion is plausible
for several reasons. First, the primary sites for amylin (AP)
and leptin action [the arcuate nucleus (ARC), but also the
VMH, see below; [107]] appeared to be activated normally
AP
amylin
NT S
synaptic
amylin
LPB
3V
input to
VMH ?
VMH
TMN
histaminergic input to VMH
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leptin
synaptic or direct leptin
input to VMH
via H1R
Fig. 2 Adiposity signal diagram. The working model assumes that
the potential role of amylin as adiposity signal requires a primary
amylin action via the area postrema (AP). AP projections via the
lateral parabrachial nucleus (LPB) reach the ventromedial hypothal-
amus (VMH) where amylin interacts with leptin. Because amylin
deficient mice have a lower expression of leptin receptors in the
mediobasal hypothalamus, the leptin/amylin interaction in the VMH
may depend on a direct action of leptin on VMH neurons; however,
the potential role of an indirect input via the hypothalamic arcuate
nucleus (ARC) requires further studies. Histamine receptors of the H1
subtype (H1R) may be involved in the leptin/amylin interaction but
the signal that triggers histamine release from neurons in the
tuberomamillary nucleus (TMN) is unknown. 3V third cerebral
ventricle
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in H1rko mice when gauged by c-Fos (amylin) and
pSTAT3 (leptin), respectively [97]. Second (see also dis-
cussion in ‘‘Pharmacological interactions of amylin with
leptin in animals’’), amylin increased leptin’s effect to
induce pSTAT3 formation in the hypothalamic ARC but
also in the VMH in obese, amylin-pretreated rats [108].
In other words, amylin restored the leptin-induced immu-
noreactivity of pSTAT3, and therefore presumably the
leptin sensitivity of the VMH, in obese rats to a level
similar to lean rats. Further, acute amylin treatment
upregulated leptin receptor expression and increased leptin
binding in the rat VMH [109]. Finally, our preliminary
studies indicated that amylin/leptin combination treatment
lowers food intake in wt but not in H1rko mice [97].
What remains to be studied is whether histamine and H1
receptors are specifically necessary for this interaction to
occur or whether they ‘‘simply’’ mediate the anorectic
effects of amylin and leptin by, in principle, independent
mechanisms.
The studies discussed above clearly implicated norad-
renergic neurons in the AP (see also ‘‘Brainstem
intracellular mechanisms mediating amylin signaling’’;
[56]) and H1 receptors presumably in the VMH [83, 96] in
amylin’s anorectic effect. We had also shown in previous
studies that the dopaminergic system may be involved in
amylin’s satiating effect because blockade of D2 receptors
attenuated amylin’s action in rats [110]. Further, immu-
nohistochemical studies showed a marked overlap of cells
with amylin-induced c-Fos expression and cells expressing
tyrosine hydroxylase (TH), the rate-limiting enzyme in
dopamine synthesis. Finally, a high density of dopamine
D2 receptors has been detected in the AP/NTS region
[111], and an infusion of the dopamine D2 antagonist
raclopride directly into the AP/NTS region attenuated the
amylin-induced reduction of feeding. Hence, we con-
cluded that a dopaminergic system in the brainstem is
involved in the ascending signaling pathway mediating the
anorectic effect of amylin. The direct relationship between
noradrenergic and dopaminergic signaling remains to be
elucidated.
All studies combined, our working model therefore
includes an interaction of the noradrenergic and possibly
dopaminergic system in the hindbrain and a sequential
involvement of hypothalamic nuclei including the hista-
minergic system in the VMH as mediators of amylin’s
anorectic effect [2, 48]. The latter may also be responsible
for the interaction of amylin and leptin. In other words, the
amylin-induced activation of AP neurons seems to lead to a
release of noradrenaline and potentially of dopamine acting
in the hindbrain [2, 13], which then directly or indirectly
influence hypothalamic histamine release to bring about
amylin’s effect by acting on hypothalamic histamine H1
receptors.
Amylin as adiposity signal (see also Fig. 2 for working
model of amylin/leptin interaction)
Introduction––distinction between satiation
and adiposity signals
The current concept of homeostatic eating controls
involves adiposity or ‘‘tonic’’ signals that enhance the
effect of satiation and other meal-associated or ‘‘episodic’’
signals. This concept helps to structure the large number of
signals implicated in the complex system controlling eat-
ing. Adiposity signals appear to affect eating by enhancing
the effects of satiation signals. For example, amylin, sim-
ilar to leptin and insulin, enhances CCK’s satiating effect
[19, 59, 112, 113].
This concept of distinct satiation versus adiposity sig-
nals also bears some discrepancies because particular
signals are not always clearly classified as either adiposity
or meal-associated signals. Insulin, e.g., has been hypoth-
esized to be an adiposity signal [114], but insulin is also
released during meals, and blockade of endogenous insulin
by insulin antibodies increased meal size [115]. Insulin
may therefore contribute to the control of meal termination.
A similar situation may apply to amylin. Although amylin,
like CCK, produces meal-terminating satiation, amylin and
CCK differ in some important aspects. In particular, rats
infused continuously with CCK do not show sustained
reductions in food intake and body weight [116]; further,
rats intraperitoneally infused with CCK prior to each
spontaneous meal had reduced meal sizes throughout the
test, but reduced total food intake and body weight were
only seen initially because of a compensatory increase in
meal frequency [117]. No such compensation occurs with
chronic amylin infusions even though the main direct
behavioral effect for CCK and amylin is a sustained
reduction in meal size [28, 81]. One could perhaps spec-
ulate that the decrease in meal size is due to a satiating
action of amylin, whereas the lack of compensatory
changes in meal frequency is due to a separate ‘‘adiposity’’
action, potentially activating other neural circuits; the latter
may not be instrumental in the case of CCK.
Because amylin appears to function as both adiposity
(see later in this section) and satiating signals, one may ask
whether tonic levels of amylin influence the satiating effect
of phasic changes in amylin levels. Data are scarce.
However, adult amylin-deficient mice eat less after acute
peripheral amylin; further, acute amylin reduced eating to a
similar extent independent of the underlying baseline
amylin concentration ([118]; see later in this section).
Hence, at least the acute effect of amylin to reduce eating
does not require pre-existing endogenous amylin nor does
the effect seem to be stronger when baseline amylin levels
are high.
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More generally, one may ask if the distinction between
adiposity versus meal-control signals is useful in light of
the current understanding of the dual actions of amylin,
insulin [114, 115, 119], and perhaps other eating controls.
The distinction would seem to be useful if the brain pro-
cessed the information differently; it could even be argued
that the utility of the concept of adiposity versus meal-
control signals only makes sense based on evidence of
distinct neural processing. In such cases, e.g., if the two
types of effects were mediated at different sites, one could
imagine that lesioning one site would prevent one effect
but not the other. Both the acute satiating effect and the
chronic adiposity effect of amylin on eating, however,
seem to require an intact AP [32, 37]. Whether subsequent
processing of the two signals in projection areas of AP
neurons depends on different brain areas or other popula-
tions of neurons has not been tested.
Evidence for amylin being an adiposity signal
Evidence indicating that amylin may act as an adiposity
signal is based on several findings. First, basal plasma
levels of amylin are increased in obese versus lean rats
[120]; of note, lean and obese rats in that study markedly
differed in age, but age per se does not seem to influence
basal amylin [121]. Second, high fat-fed obese rats had
higher baseline amylin levels than age-matched lean con-
trols [118, 122]; of note, the design of that study did not
allow distinguishing clearly between a body weight and a
diet effect. Third, basal and glucose-stimulated plasma
amylin levels were also elevated in obese humans [123,
124]. Together, these studies suggest a possible association
between body adiposity and plasma amylin.
We recently investigated in more detail whether changes
in body adiposity are reflected in altered (baseline) amylin
levels and whether such changes in adiposity and amylin
follow the same temporal pattern [125]. In that study, rats
were rendered obese by chronic intragastric overfeeding.
Plasma leptin, insulin, and amylin levels were determined
during overfeeding which was stopped when rats had
reached about 30% excess body weight above saline-
infused normal weight rats; hormone levels were deter-
mined in the same animals after the termination of
overfeeding. With the development of obesity, leptin and
insulin levels increased markedly. To our surprise, basal
amylin levels did not change significantly during this per-
iod or after termination of forced overfeeding. Based on the
studies mentioned above [118, 126], where the relative
increase in body weight was less pronounced, it seems
unlikely that the extent of overweight was insufficient to
cause major differences in plasma amylin [125]. It is,
however, possible that amylin levels may only increase
after extended periods of overweight because, in the study
by Boyle et al. [118], rats had been fed with a high fat diet
for 9 weeks, while Gloy et al. [125] measured plasma
amylin after 4 weeks of overfeeding. Further, it is possible
that the type of diet used during overfeeding may play a
role. It seems clear that further studies are required to
define the exact contribution of time, diet, extent of over-
weight, and other potential factors on the obesity-related
increase in plasma amylin levels.
A second line of evidence that amylin may act as an
adiposity signal is that chronic peripheral [30, 127] or
central [128] amylin infusion decreased body weight gain
specifically by reducing fat mass, while infusion of an
amylin antagonist increased body adiposity [26]. Body fat
loss in amylin-treated rats was even more pronounced than
in pair-fed controls, indicating that the infusions most
likely reduced eating and increased energy expenditure
[129, 130]. Further, chronic third ventricular administration
of the amylin antagonist AC187 increased food intake and
body adiposity, although body weight was unaltered [26].
Finally, the amylin knockout mouse is heavier than wild-
type controls [17], but it is not yet clear whether amylin
replacement therapy may reverse this phenotype.
Recent experiments provided insight into the specific role
of central amylin as an adiposity signal [130]; in other
words, we tested whether an elevation of central amylin
leads to a sustained change of the target body weight.
Similar to previous studies with leptin or insulin [114, 131],
we tested rats whose energy status or body weight was
manipulated, e.g., by 2-day food deprivation or by voluntary
overfeeding for 3 weeks. Interestingly, chronic third ven-
tricular amylin infusions led to lower body weight gain
irrespective of these prior manipulations. The 2-day food
deprivation led to a strong decrease in body weight in
amylin- and saline-infused control animals. At refeeding,
the saline-infused controls restored body weight rapidly to a
level that was indistinguishable from saline-infused ad libi-
tum fed rats; amylin-infused rats reached a body weight that
was similar to amylin-infused ad libitum fed rats. At ter-
mination of the study, about 2 weeks after the start of the
infusions, all amylin-infused rats had a lower body weight
than saline-infused controls. In the second experiment,
when body weight was first increased by offering an energy-
dense palatable food for 3 weeks, central amylin infusion
reduced body weight to the same level as in amylin-infused,
chow-fed rats. Together, these data suggest that central
amylin, like leptin or insulin, may encode the regulated level
of body weight and hence may contribute to the relative
constancy of body weight throughout adult life [130].
Resistance to the adiposity signals leptin and insulin
It is a well-described phenomenon that progressive obesity
is typically associated with the development of resistance
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to the eating-inhibitory effects of exogenous leptin and
insulin. In the case of leptin, a good indicator of an ani-
mal’s sensitivity to leptin is the leptin-induced induction of
pSTAT3, an intracellular signaling molecule that is
instrumental in mediating leptin function [132]; a reduced
leptin-induced pSTAT3 response in leptin target neurons
correlates with a reduced eating inhibitory effect of leptin.
Obesity-related resistance also appears to be partly due to
changes in the blood–brain barrier permeability for leptin
and insulin [133–137]; interestingly, similar but body
weight-independent changes can already be induced by a
relatively brief exposure to a high fat diet, i.e. before
obesity develops [138–140]. Finally, hyperleptinemia
which develops as a consequence of reduced sensitivity to
leptin in obesity per se seems to reduce further the animals’
sensitivity to the action of leptin [141].
Amylin sensitivity in the obese state
Much less is known about changes in the sensitivity to
amylin with the development of obesity. Such knowledge
about obesity-induced, and also high fat diet-induced,
changes in amylin sensitivity is of utmost importance
considering the potential of amylin-based pharmacotherapy
for the treatment of obesity [142–148]. Hence, it is
important to know whether similar to other adiposity sig-
nals like leptin but also to other satiating hormones like
CCK [149–151], amylin action may also be affected by
obesity or the chronic intake of diets high in fat [152].
Similar to leptin or insulin, amylin is also transported
across the blood–brain barrier [153, 154], but it is unclear
whether this transport is reduced in obesity; more impor-
tantly, even if it were reduced, a defect in amylin transport
would actually be expected to have little influence on the
biological action of amylin because of its action via the AP
which is devoid of a blood–brain barrier.
We recently tested the hypothesis that obesity reduces
the sensitivity to amylin in more detail. This included the
question if factors that cause obesity (e.g., consumption of
a high fat or palatable diet) or factors that are associated
with obesity (e.g., hyperamylinemia) change amylin sen-
sitivity independently of obesity (for details, see [118]).
Rats were chronically maintained on a high fat diet; over
the course of the study, rats seemed to retain full sensitivity
to acute amylin compared to rats fed a standard chow diet
for up to 11 weeks. Even at later time points, the acute
amylin response was not lost completely though it was
somewhat attenuated. Hence, the intake of a high fat
diet alone did not seem to markedly alter amylin sensitivity
because we would have expected to see an earlier decrease
in amylin sensitivity. The exact factors that resulted in the
attenuated sensitivity to peripheral amylin of rats main-
tained on the high fat diet are not clear. It seems plausible
that metabolic changes that occur following the prolonged
high fat diet intake and the subsequent development of
obesity may modify amylin’s efficacy; factors released
from the enlarged visceral and subcutaneous fat depots,
chronically elevated supraphysiological leptin levels or
plasma metabolites (e.g., free fatty acids or triglycerides)
alone or in combination may have contributed to the
reduced amylin sensitivity.
One factor that is associated with the development of
obesity, i.e. the increase in plasma amylin, was excluded as
a likely cause of reduced amylin sensitivity in rats exposed
to the high fat diet. As mentioned, increased circulating
levels of amylin are present in obese rats and humans [120,
123, 124, 155]. Hence, based on recent studies that
hyperleptinemia is required for the full development of
leptin resistance in rats [141], and that increased circulating
levels of CCK are implicated in a reduced sensitivity to
CCK [149], we hypothesized that elevated circulating
baseline amylin may decrease the sensitivity to acute
exogenous amylin administration. However, when lean rats
chronically infused with amylin were challenged with
acute peripheral amylin, exogenous amylin administration
decreased food intake dose-dependently under all condi-
tions; in other words, amylin acutely decreased eating to a
similar extent in all rats and regardless of circulating
amylin levels [118, 122]. Importantly, the baseline amylin
concentrations in these rats were elevated to levels that are
typically observed in obesity (30–40 vs. 10–15 pmol/l in
lean rats). Hence, at least under the experimental condi-
tions of that study, a decrease in the sensitivity to the eating
inhibitory effect of acute amylin was not apparent; down-
regulation of amylin receptors or a decrease in post-
receptor signaling following hyperamylinemia therefore
appears to be unlikely. Indirectly, the data also suggest that
the rapid rise in circulating amylin following an acute
injection, which mimics the rapid meal-induced amylin
release [122], may be more critical for amylin’s effect on
food intake, regardless of prevailing basal amylin levels.
Short term changes in amylin sensitivity and food
palatability
Highly palatable diets promote the development of obesity
in humans but also in rats; diet-induced obesity in obesity-
prone rats can, e.g., be triggered by offering a highly pal-
atable diet like liquid Ensure [156, 157]. Recent studies
suggested that food palatability and specifically the expo-
sure to Ensure can alter amylin sensitivity, at least
temporarily. Naı¨ve rats that were acutely exposed to pal-
atable chocolate Ensure for 3 days appeared resistant to the
eating inhibitory effect induced by acute central or
peripheral amylin. High doses of central amylin were still
active, suggesting that rats had not become completely
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amylin insensitive but that exposure to Ensure resulted in a
shift of the dose response curve. Interestingly, rats main-
tained on the chocolate Ensure for 3 weeks, or rats that
were switched back to a chow diet after the 3-day expo-
sure, regained amylin sensitivity [158]. The original reports
claimed that the chocolate flavor of Ensure contributes to
overeating this diet [157]. Similarly, we also found that the
chocolate flavor seems to play a key role; 3-day feeding
with neutral-flavored Ensure, which is nutritionally iden-
tical to the chocolate-flavored variety, did not result in
amylin resistance. Hence, the high palatability and the
novelty of the palatable chocolate Ensure seem to have
created a strong signal to eat that overcame the satiating
effects of acute amylin unless very high doses were used.
Whether amylin action is directly influenced by the
rewarding properties of food remains to be studied. Further,
the role of the nucleus accumbens in these effects of amylin
remains to be studied in more detail; the accumbens is
typically associated with motivational and rewarding
aspects of food [159].
To summarize, we observed reduced amylin sensitivity
under some but not all experimental conditions. Because
most of these conditions would typically be associated with
leptin resistance, it seems that the mechanisms underlying
the known instances of amylin and leptin insensitivity are
likely to be quite different. In contrast to leptin resistance,
where central leptin receptor function seems to be com-
promised, particularly in its presumed primary sites of
action in the ARC and VMH, amylin receptor function in
the AP was similar in lean chow-fed or obese rats with diet-
induced obesity, at least when gauged by c-Fos expression.
This indicates that amylin insensitivity may not be caused
by direct changes in amylin receptor function, but it needs
to be tested whether intracellular signaling systems like
cGMP and pERK, which are directly implicated in amylin
action [39, 40, 43], are affected by body adiposity or diet
composition. As mentioned before, while decreased leptin
transport across the blood–brain barrier appears to play a
role in leptin resistance [137], such an effect is unlikely to
be of relevance for amylin. Finally, while hyperleptinemia
seems required for the full development of leptin resistance
[141], rats with elevated plasma amylin seem to be fully
responsive to acute amylin injections [118, 122]. Overall,
our results suggest that amylin sensitivity seems dynamic
and may be influenced by diet composition, diet palat-
ability, time of diet exposure, and metabolic state [118,
122, 158]); however, in all cases, at least high doses of
amylin still caused a significant effect on eating.
Amylin secretion in the obese state
To search for potential causes of obesity, it is imperative to
understand the entire physiology of the controls of eating
and their role in the development of obesity. In that sense,
malfunctioning of a physiologically relevant anorectic
signaling system may not only be due to the insensitivity of
that system in obesity, or even before overt obesity
becomes apparent, but it could also be due to reduced
secretion of this factor.
Based on this background, we recently investigated how
obesity or maintenance on a high fat diet may alter eating-
induced amylin release.
As mentioned, basal levels of amylin are often elevated
in obese humans and in rodent models of obesity. How-
ever, whether the meal-contingent release of amylin is
affected by diet composition and whether the release pat-
tern differs between obese and non-obese rats had not been
tested before. In a recent study [122], we reported levels of
amylin and insulin in several groups of age-matched rats
just before and after a meal in hepatic portal vein blood
samples. The rats were high fat-fed diet-induced obese or
diet-resistant rats [157, 160, 161] or chow-fed controls.
Interestingly, both the high fat diet which had been offered
for 8 weeks and obesity appeared to influence the meal-
induced amylin release. Exposure to the high fat diet
affected the baseline amylin levels because diet-resistant
rats which actually had the lowest body weight of all
groups had elevated baseline amylin. Further, all rats on the
high fat diet demonstrated an earlier meal-induced rise in
plasma amylin compared to the chow control group.
We also analyzed the amylin-to-insulin concentration
ratio. This ratio is approximately 0.01 in lean humans and
rodents [16, 162], and it is typically elevated in the obese
state. An elevated ratio has also been reported to be asso-
ciated with chronic hyperglycemia in rats and with glucose
intolerance in obese humans [163, 164]. In our study, we
observed comparable insulin concentrations in response to
the test meal in all groups, but the diet-resistant rats had
significantly higher basal amylin-to-insulin ratios than all
other rats; this ratio remained higher than the chow-fed rats
during the meal. This finding is, in principle, in agreement
with a recent report demonstrating that elevated fatty acids
enhanced the mRNA expression and release of amylin, but
not insulin [165]. However, because the exact physiologi-
cal and clinical relevance of changes in the amylin-to-
insulin ratio is unknown, the implications of these findings
need to be studied in detail.
Overall, it seems that the differential meal-induced
secretion pattern suggests that the ratio at which amylin
and insulin are secreted during a meal is influenced by both
body composition and diet composition. We did not
observe any indication of deficient amylin secretion in
obesity or in the rats exposed to the high fat diets. In other
words, it seems very unlikely that deficient amylin secre-
tion may contribute to the development of obesity under
the conditions tested.
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Amylin and energy expenditure
Energy homeostasis not only depends on controls of energy
intake but also on controls of energy expenditure. Amylin,
similar to leptin, may influence both legs of this control
system because there are several reports from different
laboratories that acute and chronic amylin administration
increase energy expenditure in rodents [30, 127, 166, 167];
respective studies in humans have not yet been performed.
Isaksson and colleagues [166] showed that chronic
peripheral amylin reduced body adiposity more than pair
feeding in a group of control rats; this was associated with
increased fat oxidation supplying energy for increased
energy expenditure. Similarly, chronic peripheral amylin
reduced body weight and body adiposity more than in pair-
fed control rats, and amylin increased total whole body
energy expenditure [30, 127]; the latter effect may in part
have been attributable to a relative increase in metaboli-
cally more active lean body mass, because the effect
disappeared when energy expenditure was expressed per
lean body mass [127].
In our own studies, we showed that amylin increased
energy expenditure acutely when given at low doses into
the third cerebral ventricle or directly into the AP [130,
168]. A decrease in energy expenditure is the typical
metabolic reaction in weight-reduced rats; this decrease
was prevented by chronic central amylin infusion despite
its body weight-lowering effect. Amylin also lowered the
respiratory quotient in our experiments, but reports in this
respect are inconsistent. Peripheral acute administration of
amylin [67, 129], and in particular of its longer acting
agonist sCT [67, 68, 99, 130], increased energy expenditure
in rats or, as in the chronic studies mentioned above, pre-
vented the expected decrease in energy expenditure of rats
that eat less. The action of acute peripheral sCT to increase
energy expenditure was observed within minutes after
administration [129].
Overall, the studies indicate that peripheral and central
amylin seem to increase energy expenditure or at least to
prevent the compensatory decrease in energy expenditure
that is typically seen in animals that eat less or that are
weight-reduced. Even though amylin’s effect on energy
expenditure seems to be robust and has been reproduced by
various groups, the physiological relevance is not yet clear
because the role of endogenous amylin in the control of
energy expenditure has not been tested so far. In other
words, the effect of a blockade of endogenous amylin on
energy expenditure or energy expenditure in amylin-defi-
cient mice has not been studied in detail. Further, the site
and mechanisms of amylin’s actions on energy expenditure
remain to be determined. While local infusion of amylin
into the AP increased energy expenditure acutely, further
studies are necessary to clarify if the AP is necessary and
sufficient for this effect, in particular for the effect of
peripheral amylin. It is, however, likely that the effect is
mediated by the central nervous system because markedly
lower doses of amylin were highly effective when given
centrally rather than peripherally [129, 130, 167]. In terms
of mechanisms of action, it seems unlikely that increased
physical activity played an important role [129]; further,
body temperature was increased by amylin in some [129]
but not all studies, and amylin did not change the expres-
sion of uncoupling protein [127]. Whether amylin affects
heat dissipation has not yet been tested.
Pharmacological interactions of amylin with leptin
in animals
Recent research suggests that leptin and amylin interact
functionally in the control of eating. The combination of
amylin and leptin and their potent interaction are the
promising basis for the development of effective anti-
obesity therapies.
In an initial report, we found that acute central leptin
injection increased the eating-inhibitory effect of periphe-
ral amylin [169]; insulin had a similar effect on amylin
action [169, 170].
Two-week peripheral infusions of amylin and leptin
were performed in leptin-resistant rats with diet-induced
obesity; importantly, leptin doses that were effective in
lean animals were used, but the same doses had no
detectable effects on eating or body weight in obese rats
[108]. Consistent with previous reports, amylin was
effective in the obese rats because it significantly reduced
eating and led to a small, but significant, decrease in body
weight. Rats that were pair-fed to the amylin group and
that received leptin did not lose more weight than amylin-
treated rats. However, the combined application of exog-
enous leptin and amylin decreased both eating and body
weight more than amylin alone, and body fat after leptin/
amylin was lower than in rats receiving amylin or in rats
receiving leptin and that were pair-fed to amylin-treated
rats. In other words, amylin infusion enhanced the sensi-
tivity of obese rats to the catabolic effect of leptin [108].
Importantly, the leptin/amylin combination also increased
dark-phase energy expenditure [108].
Follow-up experiments using several dose combinations
confirmed the synergistic effect of amylin and leptin on
eating and adiposity [108, 109, 171]. The combinations
produced weight losses of up to 15% [144, 172]; most of
the body weight loss was due to reduced eating because
rats pair-fed to the amylin/leptin group lost similar
amounts of weight [144]. Interestingly, body fat loss was
more in the amylin/leptin-treated rats than in the pair-fed
controls, which was also observed in the study by Seth and
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colleagues [171]. This was most likely due to the decrease
in energy expenditure in pair-fed rats which was com-
pletely prevented in the amylin/leptin group [108, 109,
171]. During weight loss, the respiratory quotient was low
in both the amylin/leptin and the pair-fed groups [108,
109, 144, 171, 172], indicating preferential oxidation of
fat. However, only the amylin/leptin group maintained a
low respiratory quotient even in the weight stable phase.
These metabolic effects in the amylin/leptin rats were
paralleled by a reduced expression of genes for hepatic
lipogenesis and increased expression of genes for lipid
utilization [30, 108, 109, 146, 172]. Finally, the synergistic
effects of leptin/amylin on fat pad size were much clearer
than the effects on body weight. This is consistent with the
concept that the control mechanisms involving amylin
(and leptin) may primarily control adiposity not body
weight (see also [171]). Overall, the amylin/leptin com-
bination treatment prevented the suppression of energy
metabolism that is typically seen in situations of negative
energy balance which may, e.g., also be induced by simple
dieting.
Progress has also been made to elucidate the potential
mechanisms underlying the amylin/leptin synergy. This
interaction seems to involve a direct effect of amylin on
central leptin signaling. Most evidence points to the
hypothalamus, specifically the VMH and potentially the
ARC in that respect. The evidence is based on observations
that amylin enhanced leptin signaling (as gauged by
increased immunoreactivity of pSTAT3) specifically in the
VMH [108, 109]. This is particularly interesting in respect
to the studies discussed in the previous sections (see ‘‘Role
of histamine in amylin signaling’’) that had shown that
amylin’s eating-inhibitory effect is reduced by VMH
administration of histamine H1 receptor antagonists and
that both amylin’s and leptin’s effects on eating are blunted
in H1 receptor-deficient mice [96, 105].
Increased pSTAT3 in the VMH may be causally linked
to an amylin-induced upregulation of leptin receptor
expression and hence direct enhancement of leptin action
in VMH neurons. However, because pSTAT3 immunore-
activity was also enhanced in the AP [108], the exact site
and mechanism of interaction between amylin and leptin
require further studies; of note, the effect of even a large
dose of acute leptin to increase pSTAT3 formation in the
AP in amylin-pretreated rats was weak, and leptin did not
enhance the amylin-induced c-Fos activation of AP neu-
rons after single injection.
More evidence pointing to a hypothalamic site of
interaction was the finding that leptin binding as deter-
mined by receptor autoradiography in the rat brain was
increased in the ARC by the combination of amylin and
leptin, and by amylin alone in the VMH and other hypo-
thalamic sites, e.g., the DMH [109]. Finally, reduced leptin
receptor expression was observed in the mediobasal
hypothalamus in amylin-deficient mice [109]. It seems
plausible that all the described effects of amylin on leptin
signaling are causally linked and are part of a common
mechanism, but this still needs to be studied; this should
include the potential role of histamine and its necessity for
the functional interaction of amylin and leptin.
One further point of consideration is how the pharma-
cological interactions of amylin and leptin on eating and
adiposity relate to the physiological situation. As men-
tioned above, because rats that were pair-fed to amylin-
treated animals and received only leptin did not eat less or
lose more weight than amylin-treated rats, leptin appeared
to be unable to enhance the action of endogenous amylin
[108]. Further, another question refers to the (physiologi-
cal) relative importance of amylin and leptin in general.
Obviously, the leptin-deficient mouse has a much stronger
obese phenotype than the amylin-deficient mouse [17].
However, because obesity-associated leptin resistance
prevents leptin from being effective when the effect
apparently would be needed most, additional amylin may
be a very effective alternative. Amylin may play an
important modulatory role. In other words, the biological
spectrum of leptin, which alone seems to produce strong
signals on the ‘‘starvation side’’ (low leptin leads to a very
strong drive to eat) but is relatively less active on the
‘‘obesity side’’ (high leptin is relative ineffective in pre-
venting further eating) [173], may be extended; the
combination of amylin plus leptin seems to produce a very
effective eating inhibitory and adiposity signal, even in
obese leptin-resistant animals.
Therapeutic potential of amylin in anti-obesity therapy
The amylin analogue pramlintide has been introduced as an
adjunct to insulin into the therapy concepts of type 1 and
type 2 diabetes; this was based on pramlintide’s action to
reduce postprandial glucagon secretion and to slow gastric
emptying. Consistent with the described effects of amylin
in rodents, the combination treatment of diabetics with
insulin plus pramlintide was reported to lead to a signifi-
cant body weight loss compared to insulin monotherapy
[143]. Pramlintide has subsequently been shown to reduce
energy intake in insulin-treated type 2 diabetics but also in
obese non-diabetics [174, 175]. Pramlintide did not change
the intake of specific macronutrients but rather appeared to
decrease total eating. Further, pramlintide significantly
increased the number of treated subjects that reached a
body weight loss of more than 5% within a 16-week
treatment period [176, 177]. Even though the decrease in
total caloric intake was slightly attenuated after longer
treatment periods, pramlintide’s effect was maintained
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(e.g., total energy intake vs. control -750 kcal on day 3 of
treatment vs. -490 kcal on day 43 of treatment [177,
178]). The effect of pramlintide depended on a general
reduction in meal size but also on a reduction in unhealthy
‘‘fast food’’ intake and in the binge-eating tendency [177,
178].
Based on these studies with amylin monotherapy and the
pre-clinical work using amylin and leptin combinations in
rodents, Roth and colleagues [108, 148] tested the co-
administration of the amylin and leptin analogues, pram-
lintide and metreleptin, respectively, in overweight and
obese humans. The results were promising [108, 148]
because they indicated that this combination therapy
appeared to perform better than currently available non-
surgical approaches to treat obesity in humans. Body
weight loss was about 5% during a 4-week period when
only pramlintide was given; continued treatment with
either pramlintide or metreleptin for 20 weeks resulted in a
total body weight loss of about 8%. However, the combi-
nation treatment led to a weight loss of more than 12%, and
body weight was still on a decreasing projectory at the end
of the 5-month study. Further, the number of patients
reaching a certain percentage of body weight loss was
significantly higher in the group receiving the combination
treatment (e.g., 10% decrease in body weight: metreleptin
21%; pramlintide 35%; pramlintide ? metreleptin 56%;
15% decrease: 11, 5 and 28%, respectively). More work is
necessary to define the outcome of prolonged treatments
including potential side effects, and in particular the con-
sequences of cessation of treatment. Similar to other
chronic diseases, maintained body weight loss may require
continuous therapy, perhaps with slightly reduced doses
(see also [179, 180]).
Is there a specific role for amylin treatment in females
Most animal studies using amylin have been performed
only in male rats or mice. This is surprising, because not
only has obesity become a huge public health problem
almost worldwide but the incidence of morbid obesity in
most European countries and in the USA seems to be much
greater in women than in men. The increased obesity
burden in women is also reflected by the fact that the
majority of people undergoing bariatric surgery are
women, e.g., over 80% in the USA and Switzerland, and
the numbers seem to be similar in other countries. For this
reason, the study on sex differences in the control of eating
is important. In females, estradiol––or the lack of estra-
diol––appears to play the major role in specific effects of
the female controls of eating. Estradiol is responsible for
the cyclic decrease of eating on the day of estrus. Some of
the best investigated phenomena indicate that one action of
estradiol is to enhance the effect of endogenous satiation
signals like CCK or GLP-1 [181–187].
Recently, Trevaskis and colleagues [188] (but see also
[189]) reported that the action of (chronic) amylin on eat-
ing and body weight was stronger in ovariectomized rats
that lack estradiol than in control rats or in ovariectomized
rats receiving physiological estradiol replacement therapy;
amylin’s effect to reduce eating and body weight was about
double. This was surprising, because most previous (acute)
studies had reported an enhanced effect of satiating hor-
mones by estradiol and not by the lack of it [181, 185, 187].
In Trevaskis’ study, chronic amylin also partly restored the
metabolic rate that was decreased as a consequence of
ovariectomy [188]. Based on these results, it was con-
cluded that amylin may be a promising anti-obesity therapy
in postmenopausal women, i.e. in women with low
endogenous estradiol levels.
Despite the clear effects reported by Trevaskis et al.
[188], the interaction between amylin and estradiol seems
complex. To our surprise, experiments with acute versus
chronic amylin treatment yielded opposite effects. In other
words, single acute injections of amylin were more effec-
tive in ovariectomized rats with physiological estradiol
replacement than in rats without. Further, the amylin
antagonist AC187 increased eating more in estradiol-
replaced ovariectomized animals, pointing to the physio-
logical relevance of this effect [189, 190]. These
phenomena clearly require intensified studies; in fact, they
may represent the first principal difference in the mecha-
nisms of action of acute amylin versus chronic amylin (see
also ‘‘Introduction––distinction between satiation and adi-
posity signals’’).
Summary
Amylin is a physiological control of meal size and, like
other signals involved in satiation, the effect seems to rely
mainly on a hindbrain action, involving the AP, the NTS,
and the LPB. Chronic amylin treatment decreases while
amylin antagonist treatment increases eating and body
weight gain. This suggests that amylin may also act as an
adiposity signal. The phenotype of amylin-responsive
neurons and neurotransmitter signaling systems that are
involved in amylin action have been partly elucidated; they
seem to include noradrenergic and possibly dopaminergic
and histaminergic systems. A clinically promising finding
is that amylin seems to improve leptin sensitivity in obese
animals. Subsequent human studies indicated that amylin/
leptin combination therapy may be an effective treatment
for obesity, with efficiency beyond currently available
pharmacotherapy.
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